Welcome to our dedicated page for Tenax Therapeutics news (Ticker: TENX), a resource for investors and traders seeking the latest updates and insights on Tenax Therapeutics stock.
Tenax Therapeutics develops clinical-stage cardiopulmonary therapies, with news centered on levosimendan and TNX-103 for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). The company describes itself as a Phase 3, development-stage pharmaceutical company and reports on the LEVEL and LEVEL-2 registrational programs, intellectual property, and global development rights for levosimendan.
Recurring announcements also cover financial results, corporate updates, investor conference participation, executive appointments, and equity-based inducement grants under Nasdaq rules. These updates connect Tenax's drug-development program with governance, finance, product-development, clinical operations, and commercial-preparation activities.
Tenax Therapeutics (Nasdaq:TENX) reported first quarter 2026 results and a corporate update. Cash and equivalents were $118.8 million, expected to fund operations through at least Q1 2028. The Phase 3 LEVEL trial of TNX-103 has randomized all patients, with topline data expected in Q3 2026, while global Phase 3 LEVEL-2 enrollment is ongoing and anticipated to complete by end of 2027. Leadership additions include a new CFO, CCO and an EVP of Clinical Development and Strategy. Q1 2026 R&D expenses were $11.5 million, G&A was $5.0 million, and net loss was $15.7 million.
Tenax Therapeutics (Nasdaq: TENX) awarded inducement option grants to four newly hired non-executive employees between April 28, 2026 and June 1, 2026. The aggregate award equals 657,500 non-qualified stock options with exercise prices set at each hire date's Nasdaq close.
Vesting: 25% on the first anniversary, then 36 substantially equal monthly installments thereafter, subject to continued service. Grants were approved by the Board's Compensation Committee and issued outside the company's stockholder-approved equity incentive plan per Nasdaq Listing Rule 5635(c)(4).
Tenax Therapeutics (NASDAQ: TENX) appointed Timothy Healey, MBA as Chief Commercial Officer, effective immediately on May 4, 2026. Healey joins from Eversana and previously held senior commercial roles at Lantheus, AbbVie, and AMAG.
He will lead global commercial strategy and prepare TNX-103 and the company for a potential commercial launch, developing processes and capabilities to support commercialization.
Tenax Therapeutics (NASDAQ: TENX) appointed Thomas R. Staab, II as Chief Financial Officer, effective May 11, 2026. Mr. Staab has over 25 years of healthcare finance leadership and succeeds interim CFO Thomas McGauley. Tenax granted inducement awards: 10,000 RSUs and options to purchase 450,000 shares, vesting over one year and monthly thereafter.
The option exercise price will equal the closing common stock price on the grant date; awards were approved under Nasdaq Rule 5635(c)(4).
Tenax Therapeutics (NASDAQ: TENX) achieved randomization of 230 patients in the Phase 3 LEVEL study and expects topline results in Q3 2026. The company initiated global Phase 3 LEVEL-2 and opened an OLE study. USPTO issued a Notice of Allowance for subcutaneous levosimendan formulations. Cash was $97.6M at 12/31/2025, expected to fund operations through 2027. R&D and G&A expenses increased materially in 2025, contributing to a 2025 net loss of $52.6M versus $17.6M in 2024.
Tenax Therapeutics (Nasdaq: TENX) will participate in a fireside chat at the 2026 Leerink Partners Global Healthcare Conference in Miami, March 8-11, 2026. The presentation is scheduled for March 10, 2026 at 2:20 p.m. ET with CEO Chris Giordano, CMO Stuart Rich, and CBO Douglas Randall.
A live and archived webcast will be available on the company’s investor relations webpage.
Tenax Therapeutics (Nasdaq: TENX) will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York.
When: February 11, 2026 at 12:30 p.m. ET. Participants: Chris Giordano, President & CEO, and Douglas Randall, Chief Business Officer. A live and archived webcast will be available on the company's investor relations webpage.
Tenax Therapeutics (NASDAQ: TENX) reported that a prespecified blinded sample size re-estimation (BSSR) for the Phase 3 LEVEL trial showed the study is powered at >90% to detect a 25-meter change in 6-minute walk distance (6MWD), with observed standard deviation in the first 150 randomized patients below the assumed 55 meters. Tenax confirmed no increase in target enrollment and reiterated that LEVEL enrollment is expected to complete in the first half of 2026, with topline data expected in the second half of 2026.
The company also initiated LEVEL-2, a global Phase 3 trial planning ~540 patients randomized 2:1 (TNX-103 vs placebo) with primary endpoint 6MWD at Week 26, selecting >100 sites across 15 countries and estimating enrollment completion by end of 2027. Tenax will open a global open-label extension to provide continued access to TNX-103.
Tenax Therapeutics (NASDAQ: TENX) will present at two investor conferences in early December 2025: a fireside chat at the 8th Annual Evercore Healthcare Conference on December 2, 2025 at 4:15 p.m. ET, and a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025 at 11:30 a.m. ET.
Participants include Chris Giordano, President & CEO, and Stuart Rich, M.D., Chief Medical Officer. Live and archived webcasts will be available from the company’s investor relations webpage.
Tenax Therapeutics (NASDAQ: TENX) reported Q3 2025 results and clinical updates on Nov 12, 2025. The company expects to enroll 230 patients in the Phase 3 LEVEL study in H1 2026 with topline data H2 2026, and remains on track to initiate the global LEVEL-2 registrational study in 2025 with >160 qualified sites across 15 countries. The European Patent Office issued an Intent to Grant a patent covering levosimendan for PH-HFpEF, with a term to Dec 2040 and possible SPC extension. Cash and equivalents were $99.4M at Sept 30, 2025, with runway through 2027. Q3 operating costs rose and net loss widened to $15.8M.
The company will host a virtual KOL call on Nov 13, 2025 at 4:30 p.m. ET.